Patents Assigned to Herantis Pharma PLC.
  • TREATMENT WITH A PHARMACEUTICAL COMPOSITION COMPRISING MANF2 NUCLEIC ACID
    Publication number: 20190153052
    Abstract: A method for treating a condition in a patient, wherein the condition is selected from the group consisting of Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, stroke and peripheral neuropathy. The method consists of administering to the patient a pharmaceutically effective amount of a pharmaceutical composition comprising the MANF2 polypeptide of SEQ ID NO:2 or a functional fragment thereof.
    Type: Application
    Filed: October 17, 2014
    Publication date: May 23, 2019
    Applicant: HERANTIS PHARMA PLC.
    Inventors: Mart SAARMA, Juha LAUREN, Päivi LINDHOLM, Tonis TIMMUSK, Raimo TUOMINEN
  • Neurotrophic factor MANF and uses thereof
    Patent number: 9592270
    Abstract: The present invention generally relates to the field of treatment of neuronal disorders and more particularly to neurotrophic factor MANF and uses thereof. The present invention provides a pharmaceutical compound comprising MANF nucleic acid molecule, MANF protein or a functional fragment thereof for the treatment of a peripherial neuropathy including Alzheimer's disease, Parkinson's disease, epilepsy, drug addiction and ischemic brain injury.
    Type: Grant
    Filed: September 9, 2014
    Date of Patent: March 14, 2017
    Assignee: HERANTIS PHARMA PLC.
    Inventors: Mart Saarma, Päivi Pulkkila, Merja Voutilainen, Johan Peränen, Raimo Tuominen, Mikko Airavaara, Veli-Matti Leppänen, Maria Lindahl, Jaan-Olle Andressoo
  • MANF2 for treatment of Parkinson's disease
    Patent number: 9127082
    Abstract: The present invention discloses a novel neurotrophic factor protein, MANF2 and a genetic sequence encoding the same. The molecule will be useful in the development of a range of therapeutics and diagnostics useful in the treatment, prophylaxis and/or diagnosis of MANF2 dependent conditions. The molecule of the present invention is also a useful effector of primary and central neurons, especially dopaminergic neurons at the central nervous system and growth factor genes.
    Type: Grant
    Filed: February 26, 2008
    Date of Patent: September 8, 2015
    Assignee: HERANTIS PHARMA PLC.
    Inventors: Mart Saarma, Juha Lauren, Paivi Lindholm, Tonis Timmusk, Raimo Tuominen
  • Neurotrophic factor MANF and uses thereof
    Patent number: 8853166
    Abstract: The present invention generally relates to the field of treatment of neuronal disorders and more particularly to neurotrophic factor MANF and uses thereof. The present invention provides a pharmaceutical compound comprising MANF nucleic acid molecule, MANF protein or a functional fragment thereof for the treatment of a peripherial neuropathy including Alzheimer's disease, Parkinson's disease, epilepsy, drug addiction and ischemic brain injury.
    Type: Grant
    Filed: April 30, 2009
    Date of Patent: October 7, 2014
    Assignee: Herantis Pharma PLC.
    Inventors: Mart Saarma, Päivi Lindholm, Merja Voutilainen, Johan Peränen, Raimo Tuominen, Mikko Airavaara, Veli-Matti Leppänen, Maria Lindahl, Jaan-Olle Andressoo